Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug development

R&D plan announced for drugs for neglected diseases

The Drugs for Neglected Diseases initiative has announced that it aims to spend €650m to deliver treatments for up to 10 diseases. In the image, tsetse mosquitos pictured on a researcher's hand are responsible for the African sleeping sickness

Source: Benoît Marquet / DNDi

African sleeping sickness, transmitted by tsetse mosquitos (pictured), is one of the neglected diseases targeted by the Drugs for Neglected Diseases initiative

The Drugs for Neglected Diseases initiative, a non-profit research and development organisation, has announced that it aims to spend €650m over the next eight years to deliver 16–18 treatments for up to ten diseases.

It will continue to prioritise leishmaniasis, African sleeping sickness, Chagas disease, paediatric HIV and filarial infections. It will also launch new research and development projects for hepatitis C and mycetoma in a bid to try and deliver safe and effective quality products that are affordable to poor populations.

“DNDi will remain focused on reaching treatment targets for the most neglected diseases, but we are now in a position to apply news R&D models, where patient needs drive drug development over profits, and where prices of drugs are delinked from the cost of their development,” says Bernard Pécoul, DNDi executive director.

The group, which works in partnership with industry, public institutions, academia and non-governmental organisations, says the high cost of new drugs “has become one of the world’s most pressing and high-profile public challenges, leaving millions of patients behind”.

In its pursuit of an affordable hepatitis C drug, DNDi says it will conduct clinical trials for drug combinations consisting of recently approved therapies and clinical stage compounds in middle-income countries.

DNDi has made six treatments available since its inception in 2003, including two fixed-dose antimalaria combination therapies (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy for late-stage sleeping sickness, sodium stibogluconate and paromomycin combination therapy for visceral leishmaniasis in Africa, and a paediatric dosage form of benznidazole for Chagas disease.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069358

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The Drugs for Neglected Diseases initiative has announced that it aims to spend €650m to deliver treatments for up to 10 diseases. In the image, tsetse mosquitos pictured on a researcher's hand are responsible for the African sleeping sickness

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.